




CEDARS-SINAI®

SAMUEL OSCHIN
COMPREHENSIVE CANCER INSTITUTE



8th Annual New Therapeutics in Oncology: The Road to Personalized Medicine

Featuring The Fenmore Lectureship and The Redlich Lectureship

NOVEMBER 1-2, 2019

CONFERENCE LOCATION

Sofitel Los Angeles at Beverly Hills
8555 Beverly Blvd.
Los Angeles, CA 90048

**For the latest course information and to register,
visit cedars.cloud-cme.com/oncologycme.**

In collaboration with

UC San Diego
MOORES CANCER CENTER

ACTIVITY DETAILS AND FACULTY

This important educational activity will provide guidance to front-line and oncology clinicians, nurses, physicians, pharmacists, nurse practitioners, physician assistants and pharmacists, with the most current information available about new agents in oncology and translating of the latest research to their patients. The conference will cover drug and treatment updates with a focus on breast cancer, prostate cancer, solid tumors, melanoma and cutaneous malignancies. In addition, the conference features a mini-symposia that will explore new perspectives in chemoprevention, including active surveillance for thyroid cancer and prostate cancer as well as cancer prevention strategies.

ACCREDITATION STATEMENT

Cedars-Sinai Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Cedars-Sinai Medical Center designates this live activity for a maximum of 9.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SPECIAL ACKNOWLEDGMENT

Cedars-Sinai Medical Center also wishes to acknowledge the generosity of the Board of Governors Clinical Research Unit for its continuous support.

REGISTRATION AVAILABLE ONLINE ONLY: VISIT [CEDARS.CLOUD-CME.COM/ONCOLOGYCME](https://cedars.cloud-cme.com/oncologycme)

REGISTRATION FEES

PHYSICIANS - \$129; NON-PHYSICIANS - \$79; INDUSTRY \$229

Special one-day registration rates available online!

FACULTY

COURSE CO-DIRECTORS

*Alain Mita, MD

Co-Director, Experimental Therapeutics Program
Associate Professor of Medicine,
Department of Hematology and Oncology
Cedars-Sinai

*Monica Mita, MD

Co-Director, Experimental Therapeutics Program
Associate Professor of Medicine,
Department of Hematology and Oncology
Cedars-Sinai

*Robert Figlin, MD, FACP

Steven Spielberg Family Chair in Hematology Oncology
Director, Division of Hematology Oncology
Deputy Director, Samuel Oschin
Comprehensive Cancer Institute
Professor of Medicine and Biomedical Sciences
Cedars-Sinai

Razelle Kurzrock, MD

Chief, Division of Hematology & Oncology
Murray Professor of Medicine
Senior Deputy Director, Clinical Science
Director, Center for Personalized Cancer Therapy
& Clinical Trials Office
UC San Diego Moores Cancer Center

FACULTY

Ani Balmanoukian, MD

Director of Thoracic Oncology Associate Director of
Phase 1 Immune-Oncology Program
The Angeles Clinic and Research Institute

Adrian Bot, MD, PhD

Vice President, Scientific Affairs
Kite Pharma Inc.
A Gilead Sciences Company

Gregory Daniels, MD, PhD

Medical Oncologist
Clinical Professor of Medicine
UC San Diego Moores Cancer Center

*Stephen Freedland, MD

Warschaw Robertson Law Families Chair in Prostate Cancer
Director, Center for Integrated Research in Cancer and Lifestyle
Co-Director, Cancer Genetics and Prevention Program
Associate Director, Faculty Development
Professor, Surgery
Cedars-Sinai

*Marc Goodman, PhD

Director, Cancer Prevention and Control
Director, Community and Population
Health Research Center in the
Department of Biomedical Sciences
Professor, Medicine
Cedars-Sinai

*Allen Ho, MD

Director, Head and Neck Cancer Program
Co-Director, Thyroid Cancer Program
Associate Professor, Surgery
Cedars-Sinai

David Hoffman, MD

Tower Hematology Oncology Medical Group
Clinical Professor of Medicine
Cedars-Sinai

*John Lee, MS, LCGC

Genetic Counselor
Cedars-Sinai

Philomena McAndrew, MD

Member, Cedars-Sinai Board of Directors
Vice Chair, Pharmacy & Therapeutics Committee
Cedars-Sinai

*Heather McArthur, MD, MPH

Director, Breast Oncology
Cedars-Sinai

Rana McKay, MD

Medical Oncologist
Assistant Clinical Professor of Medicine
UC San Diego Health Services

Lawrence Piro, MD

Hematology/Oncology
President and CEO of The Angeles Clinic and Research
Institute

Barry Rosenbloom, MD

Tower Hematology
Oncology Medical Group
Clinical Professor of Medicine
Cedars-Sinai

Visiting Fenmore Lecturer

Richard S. Finn, MD

Assistant Professor of Medicine
David Geffen School of Medicine at UCLA
Department of Medicine,
Division of Hematology/ Oncology
Director, Translational Research Laboratory at UCLA

Visiting Redlich Lecturer

Gary J. Schiller, MD

Professor of Medicine
Division of Hematology/Oncology
University of California, Los Angeles
School of Medicine

**Samuel Oschin Comprehensive Cancer Institute member*

AGENDA

FRIDAY, NOVEMBER 1, 2019

Chairs: Razelle Kurzrock, MD, and Lawrence Piro, MD

1:30 p.m.	Registration
2:10	Breakthrough targets and therapeutics in the pipeline <i>Monica Mita, MD</i>
2:40	Q&A
2:50	Immunotherapy combinations <i>Ani Balmanoukian, MD</i>
3:20	Q&A
3:30	Genetics of hereditary cancer <i>John Lee, MS, LCGC</i>
4:00	Q&A
4:10	New insights for the treatment of melanoma and cutaneous malignancies <i>Gregory Daniels, MD</i>
4:40	Q&A
5:00 pm	Reception

SATURDAY, NOVEMBER 2, 2019

Chairs: Robert Figlin, MD, and Barry Rosenbloom, MD

7:30 am	Registration and breakfast
8:00	New drugs approved in 2018 and their mechanism of action <i>Alain Mita, MD</i>
8:40	Q&A
8:50	Next generation precision medicine trials <i>Razelle Kurzrock, MD</i>
9:20	Q&A
9:30	Genetically engineered T-cells for solid tumors (NO CME) <i>Adrian Bot, MD, PhD</i>
10:00	Q&A
10:10	Break
10:30-12:30 pm	Mini-Symposia: Is less more for cancer management? New perspectives in chemoprevention and active surveillance
	10:30 Active surveillance for thyroid cancer <i>Allen Ho, MD</i>
	11:00 Active surveillance for prostate cancer <i>Rana McKay, MD</i>
	11:30 Cancer chemo prevention <i>Marc Goodman, PhD</i>
	12:20 Q&A
12:50	Lunch

Chairs: Philomena McAndrew, MD and David Hoffman, MD

2:00	KEYNOTE PRESENTATION: State of the art for the treatment of prostate cancer <i>Stephen Freedland, MD</i>
2:50	Q&A
3:00	Updates on new therapeutics for hematologic malignancies <i>Gary Schiller, MD</i>
3:30	Q&A
3:40	Expert opinion for new therapeutic approaches in HCC <i>Richard Finn, MD</i>
4:10	Q&A
4:20	Integrating new therapies for the treatment of breast cancer <i>Heather McArthur, MD, MPH</i>
4:40	Q&A
5:00 pm	Closing remarks and adjourn



CEDARS-SINAI®

8797 Beverly Blvd., Suite 250
Los Angeles, CA 90048

NON-PROFIT ORG.
U.S. POSTAGE
PAID
LOS ANGELES, CA
PERMIT #22328

Earn up to 9 AMA PRA Category 1 Credits™

8th Annual New Therapeutics in Oncology: The Road to Personalized Medicine

NOVEMBER 1-2, 2019

SOFITEL LOS ANGELES
AT BEVERLY HILLS

For the latest course information and to register,
visit cedars.cloud-cme.com/oncologycme.